Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Loxo Oncology, Inc.

http://www.loxooncology.com

Latest From Loxo Oncology, Inc.

FDA OKs Blueprint/Roche's Gavreto As Rival To Lilly's Retevmo

Regulators in the US have approved Gavreto for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo.

Approvals Cancer

Roche Backs Blueprint's Precision Therapy Pralsetinib To Challenge Lilly

The collaboration between the Swiss major and Blueprint Medicines, which could be worth up to $1.7bn, should help pralsetinib provide stiff competition to Eli Lilly's RET mutation drug Retevmo.

Personalized Medicine Deals

New Drug Launches Worldwide Dipped In 2019

The number of new active substances launched in their first market in 2019 dropped as 2018’s superlative performance gave way to something more usual.

Companies Innovation

Lilly Moves Ahead With Retevmo Launch In A Challenging Environment

The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology president Anne White talked to Scrip about the launch. 

Approvals Launches
See All

Company Information

UsernamePublicRestriction

Register